CD274 and non-small cell lung carcinoma: GALAXIES Lung-201 was the Phase II, randomized, open-label study of belrestotug plus dostarlimab in patients with previously untreated locally advanced or metastatic PD-L1 high (TPS >/50%) NSCLC.